HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Hull, Elizabeth E ^a   Montgomery, McKale R ^a   Leyva, Kathryn J ^b  

^a MIDWESTERN UNIVERSITY   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENTINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MICRORNA; MOCETINOSTAT; ROMIDEPSIN; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS ASSAY; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE ASSAY; CELL DIFFERENTIATION ASSAY; COMBINATION CHEMOTHERAPY; COMPLEX FORMATION; CYTOTOXICITY ASSAY; DRUG USE; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; GENE EXPRESSION; GENE EXPRESSION ASSAY; HUMAN; IC50; IMMUNOMODULATION; INFLAMMATORY DISEASE; MACROPHAGE; MEDICAL RESEARCH; MONOCYTE; PLEIOTROPY; PROTEIN METHYLATION; REVIEW; SENESCENCE; THERMOGENESIS; ANIMAL; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; IMMUNE SYSTEM; IMMUNOLOGY; INFLAMMATION; NEOPLASMS;

ANIMALS; EPIGENESIS, GENETIC; GENETIC PLEIOTROPY; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNE SYSTEM; INFLAMMATION; NEOPLASMS;

EID: 84986327387     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/8797206     Document Type: Review

References (142)

1. M. Fournel, C. Bonfils, Y. Hou et al., "MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo," Molecular Cancer Therapeutics, vol. 7, no. 4, pp. 759-768, 2008.
2. D. M. Vigushin, S. Ali, P. E. Pace et al., "Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo," Clinical Cancer Research, vol. 7, no. 4, pp. 971-976, 2001.
3. N. Sato, T. Ohta, H. Kitagawa et al., "FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells," International Journal of Oncology, vol. 24, no. 3, pp. 679-685, 2004.
4. H. J. Kwon,T. Owa,C. A. Hassig, J. Shimada, and S. L. Schreiber, "Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase," Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 7, pp. 3356-3361, 1998.
5. Z. R. Schoepflin, I. M. Shapiro, and M. V. Risbud, "Class I and IIa HDACs mediate HIF-1 stability through PHD2-dependent mechanism, while HDAC6, a class IIb member, promotes HIF-1 transcriptional activity in nucleus pulposus cells of the intervertebral disc," Journal of Bone and Mineral Research, vol. 31, no. 6, pp. 1287-1299, 2016.
6. C. F. Deroanne, K. Bonjean, S. Servotte et al., "Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling," Oncogene, vol. 21,no. 3, pp. 427-436, 2002.
7. A. Wassef, D. J. Watson, P. Morrison, S. Bryant, and J. Flack, "Neuroleptic-valproic acid combination in treatment of psychotic symptoms: a three-case report," Journal of Clinical Psychopharmacology, vol. 9, no. 1, pp. 45-48, 1989.
8. M. Schroeder, M. O. Krebs, S. Bleich, and H. Frieling, "Epigenetics and depression: current challenges and new therapeutic options," Current Opinion in Psychiatry, vol. 23, no. 6, pp. 588-592, 2010.
9. M. Darvishi, T. Tiraihi, S. A. Mesbah-Namin, A. Delshad, and T. Taheri, "Decreased GFAP expression and improved functional recovery in contused spinal cord of rats following valproic acid therapy," Neurochemical Research, vol. 39, no. 12, pp. 2319-2333, 2014.
10. J. Y. Lee, S. Maeng, S. R. Kang et al., "Valproic acid protects motor neuron death by inhibiting oxidative stress and endoplasmic reticulumstress-mediated cytochrome c release after spinal cord injury," Journal of Neurotrauma, vol. 31, no. 6, pp. 582-594, 2014.
11. N. Khan,M. Jeffers, S. Kumar et al., "Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors," Biochemical Journal, vol. 409, no. 2, pp. 581-589, 2008.
12. P. Drogaris, V. Villeneuve, C. Pomiès et al., "Histone deacetylase inhibitors globally enhance H3/H4 tail acetylation without affecting H3 lysine 56 acetylation," Scientific Reports, vol. 2, article 220, 2012.
13. B. Barneda-Zahonero and M. Parra, "Histone deacetylases and cancer," Molecular Oncology, vol. 6, no. 6, pp. 579-589, 2012.
14. H. Liu, Q. Hu, A. J. D'Ercole, and P. Ye, "Histone deacetylase 11 regulates oligodendrocyte-specific gene expression and cell development in OL-1 oligodendroglia cells," GLIA, vol. 57, no. 1, pp. 1-12, 2009.
15. A. Villagra, F. Cheng, H.-W. Wang et al., "The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance," Nature Immunology, vol. 10, no. 1, pp. 92-100, 2009.
16. L. Bosch-Presegué and A. Vaquero, "The dual role of sirtuins in cancer," Genes and Cancer, vol. 2, no. 6, pp. 648-662, 2011.
17. L. R. Saunders and E. Verdin, "Sirtuins: critical regulators at the crossroads between cancer and aging," Oncogene, vol. 26, no. 37, pp. 5489-5504, 2007.
18. M. S. Longworth and L. A. Laimins, "Histone deacetylase 3 localizes to the plasma membrane and is a substrate of Src," Oncogene, vol. 25, no. 32, pp. 4495-4500, 2006.
19. X. Zhang, Z. Yuan, Y. Zhang et al., "HDAC6 modulates cell motility by altering the acetylation level of cortactin,"Molecular Cell, vol. 27, no. 2, pp. 197-213, 2007.
20. F. X. Soriano, S. Chawla, P. Skehel, and G. E. Hardingham, "SMRT-mediated co-shuttling enables export of class IIa HDACs independent of their CaM kinase phosphorylation sites," Journal of Neurochemistry, vol. 124, no. 1, pp. 26-35, 2013.
21. C. Choudhary, C. Kumar, F. Gnad et al., "Lysine acetylation targets protein complexes and co-regulates major cellular functions," Science, vol. 325, no. 5942, pp. 834-840, 2009.
22. I. V. Gregoretti, Y.-M. Lee, and H. V. Goodson, "Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis," Journal of Molecular Biology, vol. 338, no. 1, pp. 17-31, 2004.
23. M. A. Glozak, N. Sengupta, X. Zhang, and E. Seto, "Acetylation and deacetylation of non-histone proteins," Gene, vol. 363, pp. 15-23, 2005.
24. M. Ocker, "Deacetylase inhibitors-focus on non-histone targets and effects," World Journal of Biological Chemistry, vol. 1, no. 5, pp. 55-61, 2010.
25. K. Ververis, A. Hiong, T. C. Karagiannis, and P. V. Licciardi, "Histone deacetylase inhibitors (HDACIS): multitargeted anticancer agents," Biologics, vol. 7, no. 1, pp. 47-60, 2013.
26. K. Nakane, Y. Fujita, R. Terazawa et al., "Inhibition of cortactin and SIRT1 expression attenuates migration and invasion of prostate cancer DU145 cells," International Journal of Urology, vol. 19, no. 1, pp. 71-79, 2012.
27. B. P. Ashburner, S. D. Westerheide, and A. S. Baldwin Jr., "The p65 (RelA) subunit of NF-B interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression," Molecular and Cellular Biology, vol. 21, no. 20, pp. 7065-7077, 2001.
28. J. von Burstin, S. Eser, M. C. Paul et al., "E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex," Gastroenterology, vol. 137, no. 1, pp. 361-371. e5, 2009.
29. K. J. Falkenberg and R. W. Johnstone, "Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders," Nature Reviews Drug Discovery, vol. 13, no. 9, pp. 673-691, 2014.
30. A. C. West and R. W. Johnstone, "New and emerging HDAC inhibitors for cancer treatment,"The Journal of Clinical Investigation, vol. 124, no. 1, pp. 30-39, 2014.
31. N. Ahuja, A. R. Sharma, and S. B. Baylin, "Epigenetic therapeutics: a new weapon in the war against cancer," Annual Review of Medicine, vol. 67, no. 1, pp. 73-89, 2016.
32. S. Yoon and G. H. Eom, "HDAC and HDAC inhibitor: from cancer to cardiovascular diseases," Chonnam Medical Journal, vol. 52, no. 1, pp. 1-11, 2016.
33. E. Hu, E. Dul,C.-M. Sung et al., "Identification of novel isoformselective inhibitors within class I histone deacetylases," Journal of Pharmacology and ExperimentalTherapeutics, vol. 307, no. 2, pp. 720-728, 2003.
34. D. Wegener, C. Hildmann, and A. Schwienhorst, "Recent progress in the development of assays suited for histone deacetylase inhibitor screening," Molecular Genetics and Metabolism, vol. 80, no. 1-2, pp. 138-147, 2003.
35. K. Hoffmann,G. Brosch, P. Loidl, andM. Jung, "Anon-isotopic assay for histone deacetylase activity," Nucleic Acids Research, vol. 27, no. 9, pp. 2057-2058, 1999.
36. B. D. Marks, S. A. Fakhoury, W. J. Frazee, H. C. Eliason, and S. M. Riddle, "A substrate-independent TR-FRET histone deacetylase inhibitor assay," Journal of Biomolecular Screening, vol. 16, no. 10, pp. 1247-1253, 2011.
37. D. Riester, C. Hildmann, A. Schwienhorst, and F.-J. Meyer-Almes, "Histone deacetylase inhibitor assay based on fluorescence resonance energy transfer," Analytical Biochemistry, vol. 362, no. 1, pp. 136-141, 2007.
38. R. Furumai, A. Matsuyama, N. Kobashi et al., "FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases," Cancer Research, vol. 62, no. 17, pp. 4916-4921, 2002.
39. M. Yoshida, M. Kijima, M. Akita, and T. Beppu, "Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A," The Journal of Biological Chemistry, vol. 265, no. 28, pp. 17174-17179, 1990.
40. T. Beckers, C. Burkhardt, H. Wieland et al., "Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group," International Journal of Cancer, vol. 121, no. 5, pp. 1138-1148, 2007.
41. M. Ni, E. Esposito, V. P. Raj et al., "New macrocyclic analogs of the natural histone deacetylase inhibitor FK228; design, synthesis and preliminary biological evaluation," Bioorganic & Medicinal Chemistry, vol. 23, no. 21, pp. 6785-6793, 2015.
42. K. Saijo, T. Katoh, H. Shimodaira, A. Oda, O. Takahashi, and C. Ishioka, "Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors," Cancer Science, vol. 103, no. 11, pp. 1994-2001, 2012.
43. B. C. Valdez, J. E. Brammer, Y. Li et al., "Romidepsin targets multiple survival signaling pathways in malignant T cells," Blood Cancer Journal, vol. 5, article e357, 2015.
44. C. M. Adams, S. W. Hiebert, and C. M. Eischen, "Myc induces miRNA-mediated apoptosis in response to HDAC inhibition in hematologic malignancies," Cancer Research, vol. 76, no. 3, pp. 736-748, 2016.
45. K. Nishida, T. Komiyama, S.-I. Miyazawa et al., "Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21WAF1/Cip1 expression," Arthritis and Rheumatism, vol. 50, no. 10, pp. 3365-3376, 2004.
46. Y.-L. Chung,M.-Y. Lee, A.-J. Wang, and L.-F. Yao, "Atherapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis," MolecularTherapy, vol. 8, no. 5, pp. 707-717, 2003.
47. T. Ciossek, H. Julius, H. Wieland, T. Maier, and T. Beckers, "A homogeneous cellular histone deacetylase assay suitable for compound profiling and robotic screening," Analytical Biochemistry, vol. 372, no. 1, pp. 72-81, 2008.
48. M. Bantscheff,C. Hopf,M. M. Savitski et al., "Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes," Nature Biotechnology, vol. 29,no. 3, pp. 255-265, 2011.
49. F. Leoni, A. Zaliani, G. Bertolini et al., "The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines," Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 5, pp. 2995-3000, 2002.
50. F. Leoni, G. Fossati, E. C. Lewis et al., "The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo," Molecular Medicine, vol. 11, no. 1-12, pp. 1-15, 2005.
51. T. Sanda, T. Okamoto, Y. Uchida et al., "Proteome analyses of the growth inhibitory effects ofNCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells," Leukemia, vol. 21,no. 11, pp. 2344-2353, 2007.
52. J.-H. Cho, M. Dimri, and G. P. Dimri, "MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cellular senescence," Journal of Biological Chemistry, vol. 290, no. 16, pp. 10555-10567, 2015.
53. X.-N. Li, Q. Shu, J. M.-F. Su, L. Perlaky, S. M. Blaney, and C. C. Lau, "Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC," Molecular Cancer Therapeutics, vol. 4, no. 12, pp. 1912-1922, 2005.
54. Y. Zhai, X. Chen, D. Yu et al., "Histone deacetylase inhibitor valproic acid promotes the induction of pluripotency in mouse fibroblasts by suppressing reprogramming-induced senescence stress," ExperimentalCell Research, vol. 337, no. 1,pp. 61-67, 2015.
55. M. Malvaez, S. C. McQuown, G. A. Rogge et al., "HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner," Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 7, pp. 2647-2652, 2013.
56. F. Santoro, O. A. Botrugno, R. Dal Zuffo et al., "A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance," Blood, vol. 121, no. 17, pp. 3459-3468, 2013.
57. Y. Komatsu, K. Tomizaki, M. Tsukamoto et al., "Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity," Cancer Research, vol. 61, no. 11, pp. 4459-4466, 2001.
58. R. Soriano-Cantón, A. Perez-Villalba, J. M. Morante-Redolat et al., "Regulation of the p19Arf/p53 pathway by histone acetylation underlies neural stem cell behavior in senescence-prone SAMP8 mice," Aging Cell, vol. 14, no. 3, pp. 453-462, 2015.
59. F. Li, R. Wu, X. Cui et al., "Histone deacetylase 1 (HDAC1) negatively regulates thermogenic program in brown adipocytes via coordinated regulation of histone H3 lysine 27 (H3K27) deacetylation and methylation," The Journal of Biological Chemistry, vol. 291, no. 9, pp. 4523-4536, 2016.
60. K. Saijo, J. Imamura, K. Narita et al., "Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors," Cancer Science, vol. 106, no. 2, pp. 208-215, 2015.
61. K. Sugita,H. Yoshida,M. Matsumoto, andS. Matsutani, "Anovel compound, depudecin, induces production of transformation to the flat phenotype of NIH3T3 cells transformed by rasoncogene," Biochemical and Biophysical Research Communications, vol. 182, no. 1, pp. 379-387, 1992.
62. C. Choudhary, B. T. Weinert, Y. Nishida, E. Verdin, and M. Mann, "The growing landscape of lysine acetylation links metabolism and cell signalling," Nature Reviews Molecular Cell Biology, vol. 15, no. 8, pp. 536-550, 2014.
63. M. R. Davis, J. J. Daggett, A. S. Pascual et al., "Epigenetically maintained SW13+ and SW13 subtypes have different oncogenic potential and convert with HDAC1 inhibition," BMC Cancer, vol. 16, no. 1, pp. 1-13, 2016.
64. P.-H. Huang, C.-H. Chen, C.-C. Chou et al., "Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases," Molecular Pharmacology, vol. 79, no. 1, pp. 197-206, 2011.
65. J. A. Halsall, N. Turan, M. Wiersma, and B. M. Turner, "Cells adapt to the epigenomic disruption caused by histone deacetylase inhibitors through a coordinated, chromatin-mediated transcriptional response," Epigenetics and Chromatin, vol. 8, article 29, 2015.
66. W. Gu and R. G. Roeder, "Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain," Cell, vol. 90, no. 4, pp. 595-606, 1997.
67. J. Luo, M. Li, Y. Tang, M. Laszkowska, R. G. Roeder, and W. Gu, "Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 8, pp. 2259-2264, 2004.
68. Y. Xu, "Regulation of p53 responses by post-translational modifications," Cell Death and Differentiation, vol. 10, no. 4, pp. 400-403, 2003.
69. A. Ito, Y. Kawaguchi, C.-H. Lai et al., "MDM2-HDAC1 mediated deacetylation of p53 is required for its degradation," The EMBO Journal, vol. 21, no. 22, pp. 6236-6245, 2002.
70. Y.-H. Jin, E.-J. Jeon, Q.-L. Li et al., "Transforming growth factor-stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation," Journal of Biological Chemistry, vol. 279, no. 28, pp. 29409-29417, 2004.
71. Z.-L. Yuan, Y.-J. Guan, D. Chatterjee, and Y. E. Chin, "Stat3 dimerization regulated by reversible acetylation of a single lysine residue," Science, vol. 307, no. 5707, pp. 269-273, 2005.
72. R. Wang, P. Cherukuri, andJ. Luo, "Activationof Stat3 sequencespecific DNA binding and transcription by p300/CREBbinding protein-mediated acetylation," The Journal of Biological Chemistry, vol. 280, no. 12, pp. 11528-11534, 2005.
73. Y. Li, X. Zhang, R. D. Polakiewicz, T.-P. Yao, andM. J. Comb, "HDAC6 is required for epidermal growth factor-induced-catenin nuclear localization," The Journal of Biological Chemistry, vol. 283, no. 19, pp. 12686-12690, 2008.
74. C. Wang, M. Fu, R. H. Angeletti et al., "Direct acetylation of the estrogen receptor hinge region by p300 regulates transactivation and hormone sensitivity," Journal of Biological Chemistry, vol. 276, no. 21, pp. 18375-18383, 2001.
75. H. Kawai, H. Li, S. Avraham, S. Jiang, and H. K. Avraham, "Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor," International Journal of Cancer, vol. 107, no. 3, pp. 353-358, 2003.
76. J. H. Patel, Y. Du, P. G. Ard et al., "The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60," Molecular and Cellular Biology, vol. 24, no. 24, pp. 10826-10834, 2004.
77. S. E. Salghetti, M. Muratani, H. Wijnen, B. Futcher, and W. P. Tansey, "Functional overlap of sequences that activate transcription and signal ubiquitin-mediated proteolysis," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 7, pp. 3118-3123, 2000.
78. W. Zhang, S. Kadam, B. M. Emerson, and J. J. Bieker, "Sitespecific acetylation by p300 or CREB binding protein regulates erythroid Krüppel-like factor transcriptional activity via its interaction with the SWI-SNF complex,"Molecular and Cellular Biology, vol. 21, no. 7, pp. 2413-2422, 2001.
79. W. Zhang and J. J. Bieker, "Acetylation and modulation of erythroid Krüppel-like factor (EKLF) activity by interaction with histone acetyltransferases," Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 17, pp. 9855-9860, 1998.
80. M. A. Martinez-Balbás, U.-M. Bauer, S. J. Nielsen, A. Brehm, and T. Kouzarides, "Regulation of E2F1 activity by acetylation," The EMBO Journal, vol. 19, no. 4, pp. 662-671, 2000.
81. G. Marzio, C. Wagener,M. I. Gutierrez, P. Cartwright, K. Helin, andM. Giacca, "E2F familymembers are differentially regulated by reversible acetylation," The Journal of Biological Chemistry, vol. 275, no. 15, pp. 10887-10892, 2000.
82. J. Boyes, P. Byfield, Y. Nakatani, and V. Ogryzko, "Regulation of activity of the transcription factor GATA-1 by acetylation," Nature, vol. 396, no. 6711, pp. 594-598, 1998.
83. F. Hayakawa,M. Towatari,Y. Ozawa,A. Tomita,M. L. Privalsky, and H. Saito, "Functional regulation of GATA-2 by acetylation," Journal of Leukocyte Biology, vol. 75, no. 3, pp. 529-540, 2004.
84. T. Yamagata, K. Mitani, H. Oda et al., "Acetylation of GATA-3 affects T-cell survival and homing to secondary lymphoid organs," The EMBO Journal, vol. 19, no. 17, pp. 4676-4687, 2000.
85. J.-W. Jeong, M.-K. Bae, M.-Y. Ahn et al., "Regulation and destabilization of HIF-1 by ARD1-mediated acetylation," Cell, vol. 111, no. 5, pp. 709-720, 2002.
86. V. Sartorelli, P. L. Puri,Y. Hamamori et al., "AcetylationofMyoD directed by PCAF is necessary for the execution of the muscle program," Molecular Cell, vol. 4, no. 5, pp. 725-734, 1999.
87. A. Polesskaya and A. Harel-Bellan, "Acetylation of MyoD by p300 requires more than its histone acetyltransferase domain," The Journal of Biological Chemistry, vol. 276, no. 48, pp. 44502-44503, 2001.
88. A. Polesskaya, A. Duquet, I. Naguibneva et al., "CREB-binding protein/p300 activates MyoD by acetylation," The Journal of Biological Chemistry, vol. 275, no. 44, pp. 34359-34364, 2000.
89. L.-F. Chen,W. Fischle, E. Verdin, andW. C. Greene, "Duration of nuclear NF-B action regulated by reversible acetylation," Science, vol. 293, no. 5535, pp. 1653-1657, 2001.
90. H.-S. Kwon, H. W. Lim, J. Wu, M. Schnölzer, E. Verdin, and M. Ott, "Three novel acetylation sites in the Foxp3 transcription factor regulate the suppressive activity of regulatory T cells," Journal of Immunology, vol. 188, no. 6, pp. 2712-2721, 2012.
91. Q. Cao, J. Yu, S. M. Dhanasekaran et al., "Repression of Ecadherin by the polycomb group protein EZH2 in cancer," Oncogene, vol. 27, no. 58, pp. 7274-7284, 2008.
92. S. Glaros, G. M. Cirrincione, C. Muchardt, C. G. Kleer, C. W. Michael, and D. Reisman, "The reversible epigenetic silencing of BRM: implications for clinical targeted therapy," Oncogene, vol. 26, no. 49, pp. 7058-7066, 2007.
93. N. Yamamichi, M. Yamamichi-Nishina, T. Mizutani et al., "The Brmgene suppressed at the post-transcriptional level in various human cell lines is inducible by transientHDAC inhibitor treatment, which exhibits antioncogenic potential," Oncogene, vol. 24, no. 35, pp. 5471-5481, 2005.
94. C. Kadoch, D. C. Hargreaves, C. Hodges et al., "Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy," Nature Genetics, vol. 45, no. 6, pp. 592-601, 2013.
95. Y. Y. Sanders, T. O. Tollefsbol, B. M. Varisco, and J. S. Hagood, "Epigenetic regulation ofThy-1 by histone deacetylase inhibitor in rat lung fibroblasts," American Journal of Respiratory Cell and Molecular Biology, vol. 45, no. 1, pp. 16-23, 2011.
96. H. Jia, C. D. Morris, R. M. Williams, J. F. Loring, and E. A. Thomas, "HDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation," Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 1, pp. E56-E64, 2015.
97. T. Wada, J. Kikuchi, and Y. Furukawa, "Histone deacetylase 1 enhances microRNA processing via deacetylation of DGCR8," EMBO Reports, vol. 13, no. 2, pp. 142-149, 2012.
98. E. J. Noonan, R. F. Place, D. Pookot et al., "MiR-449a targets HDAC-1 and induces growth arrest in prostate cancer," Oncogene, vol. 28, no. 14, pp. 1714-1724, 2009.
99. H. J. Bae, K. H. Jung, J. W. Eun et al., "MicroRNA-221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer," Journal ofHepatology, vol. 63,no. 2, pp. 408-419, 2015.
100. T. Qiu, L. Zhou,W. Zhu et al., "Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials," Future Oncology, vol. 9, no. 2, pp. 255-269, 2013.
101. M. Slingerland, H.-J. Guchelaar, and H. Gelderblom, "Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors," Anti-Cancer Drugs, vol. 25, no. 2, pp. 140-149, 2014.
102. N. Ahuja, H. Easwaran, and S. B. Baylin, "Harnessing the potential of epigenetic therapy to target solid tumors," The Journal of Clinical Investigation, vol. 124, no. 1, pp. 56-63, 2014.
103. L. Andresen, H. Jensen, M. T. Pedersen, K. A. Hansen, and S. Skov, "Molecular regulation of MHC class I chain-related protein A expression after HDAC-inhibitor treatment of jurkat T cells,"TheJournal of Immunology, vol. 179, no. 12, pp. 8235-8242, 2007.
104. J. S. Waby, H. Chirakkal, C. Yu et al., "Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line," Molecular Cancer, vol. 9, article 275, 2010.
105. M. D. Cantley, D. P. Fairlie, P. M. Bartold, V. Marino,P. K. Gupta, and D. R. Haynes, "Inhibiting histone deacetylase 1 suppresses both inflammation and bone loss in arthritis," Rheumatology, vol. 54, no. 9, pp. 1713-1723, 2015.
106. N. Mishra, C. M. Reilly,D. R. Brown, P. Ruiz, and G. S. Gilkeson, "Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse," The Journal of Clinical Investigation, vol. 111, no. 4, pp. 539-552, 2003.
107. N. Mishra, D. R. Brown, I. M. Olorenshaw, and G. M. Kammer, "Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gene and protein expression in lupus T cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 5, pp. 2628-2633, 2001.
108. X. Wu, Y. Tao, J. Hou, X. Meng, and J. Shi, "Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma," Neoplasia, vol. 14, no. 12, pp. 1178-1189, 2012.
109. S. Armeanu, M. Bitzer, U. M. Lauer et al., "Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate," Cancer Research, vol. 65, no. 14, pp. 6321-6329, 2005.
110. D. M. Woods, A. L. Sodre, A. Villagra, A. Sarnaik, E. M. Sotomayor, and J. Weber, "HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade," Cancer Immunology Research, vol. 3, no. 12, pp. 1375-1385, 2015.
111. S. Skov, M. T. Pedersen, L. Andresen, P. T. Straten, A. Woetmann, and N. Dum, "Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B," Cancer Research, vol. 65, no. 23, pp. 11136-11145, 2005.
112. K. V. Woan, M. Lienlaf, P. Perez-Villaroel et al., "Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: enhanced antitumor immunity and impaired cell proliferation," Molecular Oncology, vol. 9, no. 7, pp. 1447-1457, 2015.
113. J. Manning, M. Indrova, B. Lubyova et al., "Induction of MHC class Imolecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours," Immunology, vol. 123, no. 2, pp. 218-227, 2008.
114. D. M. Woods, K. Woan, F. Cheng et al., "The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity," Melanoma Research, vol. 23, no. 5, pp. 341-348, 2013.
115. R. Di Liddo, S. Valente, S. Taurone et al., "Histone deacetylase inhibitors restore IL-10 expression in lipopolysaccharideinduced cell inflammation and reduce IL-1 and IL-6 production in breast silicone implant in C57BL/6J wild-type murine model," Autoimmunity, 2016.
116. F. Cheng, M. Lienlaf, P. Perez-Villarroel et al., "Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells," Molecular Immunology, vol. 60, no. 1, pp. 44-53, 2014.
117. F. Cheng, M. Lienlaf, H.-W. Wang et al., "A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs," Journal of Immunology, vol. 193, no. 6, pp. 2850-2862, 2014.
118. A. F. Setiadi, K. Omilusik, M. D. David et al., "Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors," Cancer Research, vol. 68, no. 23, pp. 9601-9607, 2008.
119. I. M. Adcock, "HDAC inhibitors as anti-inflammatory agents," British Journal of Pharmacology, vol. 150, no. 7, pp. 829-831, 2007.
120. C. A. Dinarello, "Anti-inflammatory agents: present and future," Cell, vol. 140, no. 6, pp. 935-950, 2010.
121. C. A. Dinarello, G. Fossati, and P. Mascagni, "Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer," Molecular Medicine, vol. 17, no. 5-6, pp. 333-352, 2011.
122. A. J. P. Edwards and S. L. F. Pender, "Histone deacetylase inhibitors and their potential role in inflammatory bowel diseases," Biochemical Society Transactions, vol. 39, no. 4, pp. 1092-1095, 2011.
123. W. W. Hancock, T. Akimova, U. H. Beier, Y. Liu, and L. Wang, "HDAC inhibitor therapy in autoimmunity and transplantation," Annals of the Rheumatic Diseases, vol. 71, supplement 2, pp. i46-i54, 2012.
124. B. W. Bridle, L. Chen, C. G. Lemay et al., "HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy,"MolecularTherapy, vol. 21, no. 4, pp. 887-894, 2013.
125. L. Larsen,M. Tonnesen, S. G. Ronn et al., "Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells," Diabetologia, vol. 50, no. 4, pp. 779-789, 2007.
126. S. J. Shuttleworth, S. G. Bailey, and P. A. Townsend, "Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases," Current Drug Targets, vol. 11, no. 11, pp. 1430-1438, 2010.
127. G. Faraco, L. Cavone, and A. Chiarugi, "The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis,"MolecularMedicine, vol. 17, no. 5-6, pp. 442-447, 2011.
128. S. Camelo, A. H. Iglesias,D. Hwang et al., "Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis," Journal of Neuroimmunology, vol. 164, no. 1-2, pp. 10-21, 2005.
129. A. S. Fiorino and I. Zvibel, "Disruption of cell-cell adhesion in the presence of sodium butyrate activates expression of the 92 kDa type IV collagenase in MDCK cells," Cell Biology International, vol. 20, no. 7, pp. 489-499, 1996.
130. M. J. LaBonte, P. M. Wilson,W. Fazzone, S. Groshen, H.-J. Lenz, and R. D. Ladner, "DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines," BMC Medical Genomics, vol. 2, article 67, 2009.
131. E. Bandres, X. Agirre, N. Bitarte et al., "Epigenetic regulation of microRNA expression in colorectal cancer," International Journal of Cancer, vol. 125, no. 11, pp. 2737-2743, 2009.
132. S. Diederichs and D. A. Haber, "Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing," Cancer Research, vol. 66, no. 12, pp. 6097-6104, 2006.
133. K.-T. Lin, Y.-W. Wang, C.-T. Chen, C.-M. Ho,W.-H. Su, and Y.-S. Jou, "HDAC inhibitors augmented cell migration and metastasis through induction of PKCs leading to identification of lowtoxicitymodalities for combination cancer therapy," Clinical Cancer Research, vol. 18, no. 17, pp. 4691-4701, 2012.
134. E. Benito, H. Urbanke, B. Ramachandran et al., "HDAC inhibitor-dependent transcriptome and memory reinstatement in cognitive decline models," Journal of Clinical Investigation, vol. 125, no. 9, pp. 3572-3584, 2015.
135. A. S. Sewal, H. Patzke, E. J. Perez et al., "Experience modulates the effects of histone deacetylase inhibitors on gene and protein expression in the hippocampus: impaired plasticity in aging," TheJournal ofNeuroscience, vol. 35,no. 33,pp. 11729-11742, 2015.
136. S. Aslibekyan, E. W. Demerath, M. Mendelson et al., "Epigenome-wide study identifies novel methylation loci associated with body mass index and waist circumference," Obesity, vol. 23, no. 7, pp. 1493-1501, 2015.
137. S. Keleg, P. Büchler, R. Ludwig, M. W. Büchler, and H. Friess, "Invasion and metastasis in pancreatic cancer," Molecular Cancer, vol. 2, article 14, 2003.
138. L. Robert, A. Ribas, and S. Hu-Lieskovan, "Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2" Seminars in Immunology, vol. 28, no. 1, pp. 73-80, 2016.
139. S. S. Ramalingam,M. L. Maitland, P. Frankel et al., "Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer," Journal of Clinical Oncology, vol. 28, no. 1, pp. 56-62, 2010.
140. D. A. Yardley, R. R. Ismail-Khan, B. Melichar et al., "Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptorpositive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor," Journal of Clinical Oncology, vol. 31, no. 17, pp. 2128-2135, 2013.
141. M. Balliu, L. Guandalini, M. N. Romanelli, M. D'Amico, and F. Paoletti, "HDAC-inhibitor (S)-8 disruptsHDAC6-PP1 complex prompting A375 melanoma cell growth arrest and apoptosis," Journal of Cellular andMolecularMedicine, vol. 19,no. 1, pp. 143-154, 2015.
142. L. Shen, A. Orillion, and R. Pili, "Histone deacetylase inhibitors as immunomodulators in cancer therapeutics," Epigenomics, vol. 8, no. 3, pp. 415-428, 2016.